Inventor

BOHLMANN ROLF

DE64 patents

⚠️ This page may combine multiple inventors who share the name “BOHLMANN ROLF”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BOHLMANN ROLF

SCHERING AG

Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents

N-substituted imidazoles as aromatase inhibitors

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones

11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring

Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents

7 α-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7 α(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents

7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents

N-substituted imidazoles, as well as their use in pharmaceutical agents

Cycloalkylene azoles and their use as aromatase inhibitors

N-substituted imidazoles and their use in pharmaceutical agents

3-methylene-4-androsten-17-ones, process for their production and pharmaceutical preparations containing them

11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β LONG-CHAIN SUBSTITUTED ESTATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS

7α-(xi-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(xi-aminoalkyl-estratrienes as well as their use for the production of pharmaceutical agents

Antiestrogens, process for their production and their pharmaceutical use

7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents

11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS

11β-substituted 14,17-ethanoestratrienes, process for their production and their use as pharmaceutical agents

14,17α-etheno- and -ethanoestratrienes, processes for the preparation of these compounds, as well as their use for the production of medicinal agents

Process for the production of 17α-ethinyl-17β-hydroxy-18-methyl-4,15-estradien-3-one and new intermediate products for this process

Antiestrogens, process for their production and their pharmaceutical use

17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17α-ALKYL-17β-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS

Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents

17-halomethylene estratrienes

Functionalized vinyl azoles and methods of use

N-fluorosulfonimides, process for their production, as well as their use as fluorinating agents

Cycloalkylene azoles, and their use as aromatase inhibitors

Cycloalkylene azoles and pharmaceutical preparations obtained therefrom

Benzocycloheptenes, process for their production, pharmaceutical preparations that contain that latter as well as their use for the production of pharmaceutical agents

Antiestrogens, process for their protection and their pharmaceutical use

BAYER SCHERING PHARMA AG

Androgenic 7-substituted 11-halogen steroids

18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same

Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations

Bayer Pharma AG

Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group

4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group

5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group

5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group

KLAR ULRICH

Substituted imidazopyridazines

Substituted imidazopyrazines

15, 16-methylene-17-(1′-propenyl)-17,3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative

17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivative, use thereof, and medicament containing the derivative

Lücking Ulrich

Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group

4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group

Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines

Disubstituted 5-fluoro-pyrimidines

KOPPITZ MARCUS

Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors

6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors

BAYER IP GMBH

4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group